Business Wire

NEUSTAR

14.1.2020 09:02:07 CET | Business Wire | Press release

Share
Neustar Delivers UltraThreat Feeds for More Effective Data Security

Neustar® , Inc., a global information services company and leader in identity resolution, today announced the release of UltraThreat Feeds, a new service that provides its enterprise customers with access to real-time threat data to help them better identify cyber threats as they evolve. Designed by Neustar’s renowned security experts and leading academic researchers, the service – unique to Neustar – enables security and threat intelligence teams of all sizes to access threat feeds based on analysis and observations curated from Neustar’s expansive DNS, OneID and IP decisioning data.

Incorporating proprietary data derived from Neustar’s Security Portfolio & OneID identity resolution platform, UltraThreat Feeds can be ingested into a client’s existing platform to deliver superior threat data and provide valuable insights to unique and developing threats in near real-time.

“With the average cost of a data breach now at nearly $4 million, enterprises are investing significant resources into threat intelligence solutions to better defend themselves. A key change is enabling network and application security tools with improved real-time awareness of active threats,” said Rodney Joffe, security CTO, senior technologist and fellow at Neustar. “For example, SIEMs, TIPs, Next Gen Firewalls, IPS/IDS, WAFs, and DNS Firewalls all require threat data to power their security functions to detect and block malicious actors. Neustar’s UltraThreat Feeds service delivers deep, rich threat data, giving users the power to identify indicators of compromise or malicious activity in near real time and act accordingly to limit or even prevent attacks.”

UltraThreat Feeds enable Neustar customers to identify:

  • Malicious Domain Generation Algorithms (“DGAs”) – When malicious actors register one of the thousands of domains that are created by the DGAs within their malware, and that then allow the actors to control infected hosts from their Command and Control Servers (C2).
  • Suspicious DNS Tunneling Attempts – When Domains leverage the DNS protocol to create a “tunnel” to exfiltrate data past customers’ security measures.
  • Newly Observed Domains – When a Domain with little or no history is suddenly active, which presents increased risk.
  • Domain Updates (Nameserver or Hosting IP Address) – When there are indications that a domain has been hijacked.
  • Domain Spoofing (Business Email Compromise) – When fake online personas trick victims into making fraudulent transactions by imitating or resembling legitimate domains.

Neustar’s UltraThreat Feeds service has an advantage over competitors, thanks to the availability of its own unique data assets, including DNS data exhaust collected from the more than 100 billion queries received from 30 globally distributed nodes every day and supplemented by the IP address intelligence and analytics processed across Neustar’s product suite. Combined with behavioural analysis and pattern-based research, this advantage enables Neustar to derive truly unique insights into malicious activity. With insight gained from Neustar’s globally distributed authoritative and recursive DNS network, Neustar OneID, IP Intelligence geolocation and risk data, UltraThreat Feeds can provide a proprietary view of global threats to help identify and stop bad traffic, both inbound and outbound.

"With increasing attacker sophistication, and renewed aggression from nation-state adversaries focused on corporate espionage, many organisations are trying to find out how to properly leverage these [threat intelligence] services to protect themselves," wrote Forrester analysts Josh Zelonis and Joseph Blankenship in the report, The Forrester Tech Tide™: Zero Trust Threat Detection And Response, Q1 2019.

For more technical details on Neustar UltraThreat Feeds, visit https://www.home.neustar/security-intelligence/ultra-threat-detection-feeds .

-ENDS-

About Neustar

Neustar is an information services and technology company and a leader in identity resolution providing the data and technology that enables trusted connections between companies and people at the moments that matter most. Neustar offers industry-leading solutions in Marketing, Risk, Communications, Security and Registry that responsibly connect data on people, devices and locations, continuously corroborated through billions of transactions. Neustar serves more than 8,000 clients worldwide, including 60 of the Fortune 100. Learn how your company can benefit from the power of trusted connections here: www.home.neustar .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse

Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe

Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release

Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye